Metabolic profile performed better than other markers for predicting fibrosis progression: ALT (AUROC 0.59, 95% CI: 0.48–0.71, p = 0.08), AST (AUROC 0.65, 95% CI: 0.52–0.76, p = 0.006), FIB-4 (AUROC 0.5, 95% CI: 0.39–0.61, p = 0.9), NAFLD fibrosis score (AUROC 0.56, 95% CI: 0.44–0.67, p = 0.26) and LSM at baseline (AUROC 0.43, 95% CI: 0.31–0.55, p = 0.2) (Figure 1). This evidence concerns the gene GPT and metabolic dysfunction-associated steatotic liver disease.